Skip to content

Risk assessment for chronic coronary heart disease by general practitioners: Using the Cardio Explorer in primary care

Pilot study on using the Cardio Explorer for coronary heart disease risk assessment in primary care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN67912485
Enrollment
446
Registered
2024-09-11
Start date
2024-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease Circulatory System

Interventions

This is a multicentre, controlled, non-randomized study with prospective observation of both the intervention and control groups (quasi-experimental study design). Patients included in the study duri

Sponsors

AOK
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Insured with AOKN at the time of inscription and for the duration of study 2. Age =50 years 3. Suspected coronary heart disease 4. Residing in Niedersachsen or bordering area

Exclusion criteria

Exclusion criteria: 1. Pre-existing diagnosis of coronary heart disease 2. Acute coronary syndrome / other medical emergencies 3. Participation in any clinical study (self-report) 4. Participation in the control group disqualifies from participation in the intervention group

Design outcomes

Primary

MeasureTime frame
Concordance between the recommended medical actions based on the Cardio Explorer risk class and the medical (diagnostic) procedure, both assessed during the intervention phase. The Cardio Explorer risk class is determined for each patient at one point throughout individual treatment (application of the Cardio Explorer). The medical (diagnostic) procedure determined by the GP is assessed at the end of treatment for each patient using a self-developed questionnaire (electronic Case Report Form).

Secondary

MeasureTime frame
1. The GPs’ ratings on the benefit of facilitation of risk assessment are measured using a self-developed questionnaire at the end of treatment for each patient (electronic Case Report Form). Ratings on the benefit of the risk assessment derived from qualitative interviews with GPs at the end of the intervention phase are considered as well. 2. The confidence among GPs in the risk assessment of the Cardio Explorer measured using a self-developed questionnaire at the end of treatment for each patient (electronic Case Report Form) during the intervention phase 3. GPs' good usability and practicality (usefulness, ease of use, ease of learning and satisfaction) of the Cardio Explorer measured using the standardized USE questionnaire (Usefulness, Satisfaction and Ease of use) at the end of the intervention phase. Subjective ratings (advantages and disadvantages) regarding the implementation of the Cardio Explorer derived from qualitative interviews are considered. 4. The effects on the indication for diagnostic procedures measured via the type and number of diagnostic procedures based on claims data during the follow-up period. In addition, the subjective ratings of the GPs on the reduction of unnecessary diagnostic procedures derived from qualitative interviews at the end of the intervention phase are considered. 5. The effects on the demand for treatment by cardiologists are measured by the number of patient visits to cardiologists based on claims data (follow-up period) as well as subjective ratings among GPs derived from qualitative interviews at the end of the intervention phase.

Countries

Germany

Contacts

Public ContactMonika Sander
cardioexplorer@iges.com+49 30 230 809 44

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 9, 2026